Differences in Hematological and Clinical Features Between Essential Thrombocythemia Cases With JAK2- or CALR-Mutations
The authors describe the differences between patients with essential thrombocythemia who have either JAK2- or CALR-mutations. Mutations in JAK2 or CALR are present in about 50% and 25% of patients with essential thrombocythemia, respectively, and these mutations are thought to drive myeloproliferative neoplasms (MPNs). CALR and JAK2 mutations are mutually exclusive in MPNs.
Ann Lab Med
In The News
Oncology Nurse Advisor
Dose-Escalation Mitigates Risk of Grade 3/4 Adverse Events With Ruxolitinib for Myelofibrosis
American Journal of Managed Care
New Guideline Released on Managing Complications in Polycythemia Vera
Oncology Nurse Advisor
Case Study: Myelofibrosis Diagnosis and Early Intervention
In The Literature
Blood (ASH Abstract)
A Phase 2 Study of the Safety and Efficacy of INCB050465, a Selective PI3Kδ Inhibitor, in Combination With Ruxolitinib in Patients with Myelofibrosis
Blood (ASH Abstract)
Independent Association of Male Sex With Presentation and Clinical Outcomes in Myeloproliferative Neoplasms
American Journal of Hematology
Myeloproliferative Neoplasms in the Young: Mayo Clinic Experience With 361 Patients Age 40 Years or Younger
European Journal of Haematology